AbbVie and the associated logos are trademarks of AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company committed to developing advanced therapies for complex and chronic diseases, including a longstanding focus on liver disease. Leveraging decades of expertise in virology and immunology, AbbVie has led groundbreaking innovations in the treatment of chronic hepatitis C virus (HCV) infection, while actively expanding into novel therapeutic areas such as MASH (Metabolic dysfunction-associated steatohepatitis) and MASLD (Metabolic dysfunction-associated steatotic liver disease).

AbbVie’s HCV portfolio, including Mavyret® (glecaprevir/pibrentasvir), is a pan-genotypic, once-daily, short-course regimen that has redefined the standard of care. With cure rates consistently above 95%, Mavyret has made a significant global impact on the hepatitis C epidemic, offering a highly effective and well-tolerated treatment option for a broad patient population, including those with renal impairment or compensated cirrhosis.

Building on its liver care foundation, AbbVie is advancing research in MASH/MASLD, a major cause of liver-related morbidity and mortality worldwide. The company’s investigational MASH/MASLD candidates target multiple disease mechanisms, including metabolic dysfunction, inflammation, and fibrosis. Notably, AbbVie’s dual agonist of GLP-1 and glucagon receptors is being developed to address both the hepatic and systemic features of MASH/MASLD, reflecting the company’s commitment to multi-modal therapeutic strategies.

With a pipeline rooted in biology-driven innovation, AbbVie continues to integrate advanced technologies and translational research to accelerate progress in hepatology. The company is also committed to health equity, access, and global partnerships to improve liver health outcomes across diverse populations.

Through its portfolio of approved therapies and pipeline candidates, AbbVie remains a key player in the evolution of liver disease treatment—driven by a vision to provide lasting impact for patients around the world.